Importance

Loading Importance Indicators...

Abstract

The present invention relates to a novel pharmaceutical combination, containing an inhibitor of platelet aggregation and a fÊbrate, where the inhibitor of platelet aggregation is preferably either aspirin or clopidogreL Such a pharmaceutical combination of an inhibitor of platelet aggregation and a fÊbrate is expected to be useful in the treatment and/or prevention of myocardial infarction (heart attack), cardiac arrest, peripheral vascular disease (including symptomatic carotid artery disease), congestive heart failure, ischemic heart disease, angina pectoris (including unstable angina), sudden cardiac death, unstable angina, as well as cerebrovascular events such as cerebral infarction, cerebral thrombosis, cerebral ischemia and transient ischemic attack, disorders related to bypass operations (angioplasty), fitting of endovascular prostheses and restenosis, and inflammatory disorders, including arthritic conditions such as rheumatoid arthritis and osteoarthritis, as well as asthma or related airway or respiratory inflammatory disorders.

Loading the Abstract Image...

First Claim